We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




A Non-Invasive Skin Test Accurately Diagnoses Covid-19

By LabMedica International staff writers
Posted on 21 Jul 2022
Print article
Image: Test tube with swab for coronavirus analysis (Photo courtesy of 123rf.com)
Image: Test tube with swab for coronavirus analysis (Photo courtesy of 123rf.com)

Metabolic changes caused by Covid-19 infection can be detected in skin and saliva samples as well as in the blood, which suggest that noninvasive diagnostic tests for the disease could be available in the near future.

Investigators at the University of Surrey (United Kingdom) analyzed the correlations between serum metabolites, salivary metabolites, and skin sebum lipids in Covid-19 positive and negative individuals. In this study, 83 Covid-19 positive and negative hospitalized participants provided blood serum alongside saliva and sebum samples for analysis by liquid chromatography mass spectrometry. Participants were requested to provide all three biofluids, but due to declined consent for blood sampling, or inability to express saliva or easily provide blood, not all participants provided all three biofluids. All samples (sebum, saliva, and serum) were taken from each patient within 20 minutes of one another.

Results revealed widespread alterations to serum-sebum lipid relationships in Covid-19 positive participants versus negative controls. There was also a marked correlation between sebum lipids and the immunostimulatory hormone dehydroepiandrosterone sulfate in the Covid-19 positive group.

The biofluids were also compared in terms of their ability to differentiate COVID-19 positive participants from controls. Thus, serum performed best by multivariate analysis (sensitivity and specificity of 0.97), with the dominant changes in triglyceride and bile acid levels, in agreement with other studies identifying dyslipidemia as a hallmark of Covid-19 infection. Sebum performed well (sensitivity 0.92; specificity 0.84), with saliva performing worst (sensitivity 0.78; specificity 0.83). These findings confirmed that alterations to skin lipid profiles coincided with dyslipidaemia in serum.

Senior author Dr. Melanie Bailey, reader in analytical science the University of Surrey, said, "Covid-19 has shown us that rapid testing is vital in monitoring and identifying new illnesses. In our research, we explored the relationships between different biofluids, and what changes in one part of the human body can tell us about the overall health of a patient. Our results show that, while blood is the most accurate way of testing for this virus, skin swabs are not too far behind - in fact, the skin swab results were surprisingly accurate."

The study was published in the July 13, 2022, online edition of the journal Scientific Reports.

Related Links:
University of Surrey 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.